Resources

WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination and help healthcare providers in the assessment and management of potential TTS cases following vaccination with a COVID-19 adenovirus vector-based vaccine.

This tool is provided to support countries in assessing programme readiness to introduce COVID-19 vaccines; identifying gaps and prioritizing actions for enhanced readiness; and identifying opportunities for financial support through the World Bank's Health, Nutrition, and Population (HNP) portfolio to help countries optimize vaccine delivery and use.

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). This document has been updated: Update 23 February 2022.

These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). Updated 15 march 2022

This background document on the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 has been prepared by the Working Group on COVID-19 Vaccines of the Strategic Advisory Group of Experts (SAGE) on Immunization to inform SAGE deliberations. It contains the evidence summary which was considered by SAGE and served as the foundation for the WHO Interim recommendations for use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19.

The objective of this course is to describe how statistical reasoning and algorithms may bring value in pharmacovigilance, explain the idea of disproportionality analysis and compute different measures of disproportionality.

The aim of this course is understand the complex nature of causality assessment in Individual Case Safety Reports (ICSRs) and the value of structured approaches.

The course recognizing and managing anaphylaxis provides practical guidance to the frontline health care providers and also vaccinators key information on its identification, differentiating it from other clinical conditions such as fainting and other stress related responses. It also provides step by step guidance on the case management at the site of the event and the process of referral.

The Access to COVID-19 Tools (ACT) Accelerator's Country Readiness and Delivery workstream has released guidance on developing a national deployment and vaccination plan (NDVP) for COVID-19 vaccines. This course is intended to help national and sub-national focal points in countries develop the NDVP and prepare for COVID-19 vaccine introduction.

The objective of this document is to provide guidelines to national immunization programs (NIPs) for the development of their COVID-19 vaccination plans.

This document is a guide to facilitate the preparation of a risk communication and community engagement strategy for vaccination against COVID-19.

This good practice statement has been developed based on the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 11 August 2022.

These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). Update 15 March 2022

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.

The aim of this course is understand the complex nature of causality assessment in Individual Case Safety Reports (ICSRs) and the value of structured approaches. understand the important elements to consider when assessing causality in a case series and the relevance of the Bradford Hill criteria.

The aim of this course is to introduce strategies, terminologies and tools that ensure the standardized management of ADR reports and enable effective handling and analysis of drug/vaccine safety data in your pharmacovigilance centre.

This eLearning course introduces participants to the foundations of vaccine pharmacovigilance. The aim of this course is to provide healthcare professionals whose work involve vaccine safety issues, with essential knowledge about vaccines and their safety aspects.

This infodemic management course applies evidence-based guidance to the COVID-19 pandemic. It covers key risk communication and community engagement (RCCE) principles and illustrates how they can be operationalized in the context of an extended outbreak that affects different populations with varying risk levels.

This video shows how to store, thaw and administer the Modern COVID-19 vaccine and the differences from other vaccines.

This reference document lists and provides internationally standardized case definitions of adverse events of special interest and adverse events following immunization for COVID-19 vaccines.

This field guide has been adapted from the WHO report Vaccine Introduction Guidelines: Adding a Vaccine to a National Immunization Programme: Decision and Implementation.

This Good Practice Statement summarizes current evidence on these variant-containing mRNA vaccines and provides guidance on their use in the context of the continued availability of ancestral virus-based COVID-19 vaccines. Updated 20 February 2023

These WHO interim recommendations on the use of the Moderna mRNA-1273 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). This document has been updated: Update 18 August 2022 This document has been updated: Version 23 February 2022.

These WHO interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). 19 May 2022

This document presents the evidence related to coadministration of Covid-19 and influenza vaccines and the interim guidance.

The Framework is intended to be helpful to policy makers and expert advisors at the global, regional and national level as they make allocation and prioritization decisions about COVID-19 vaccines.

This video shows how to recognize anaphylaxis and how to differentiate between anaphylaxis and a stress-related response to immunization.

This course covers basic concepts as well as the history, need, aims and scope of pharmacovigilance. It serves as an introduction for anyone with an interest in pharmacovigilance.

The purpose of this document is to provide guidance for countries to develop and strengthen supply chain strategies to receive, store, distribute and manage COVID-19 vaccines and their ancillary products.

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE).This document has been updated: Version 18 August 2022.

These WHO interim recommendations on the use of the Valneva VLA2001vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE).This document has been updated: Version 18 August 2022

interim statement on vaccination against COVID-19 for children

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). updated 15 March 2022

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE). This document has been updated: 15 March 2022.

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE).This document has been updated: Version 21 January 2022.

This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).

This training is intended for health workers, decision-makers, and the public and covers correct mask use for both healthcare and community settings.

This course provides general information on COVID19 and specific information on vaccine storage, handling and administration, recording and monitoring of vaccination, including post-immunization adverse event surveillance and communication.The original English version of this course can be found at OPENWHO.ORG

All health workers involved in implementation of COVID-19 vaccination need to have adequate knowledge and skills in order to ensure safe and efficient COVID-19 vaccine administration. The COVID-19 vaccination training for health workers package is developed for frontline health workers in countries

The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced. Countries should include preparedness plans for COVID-19 vaccine safety in their overall plans for vaccine introduction, building on WHO guidance.

This guidance will be useful for managers in the areas of immunization and vaccine and vaccination safety. They will also help preparedness and response teams working in safety crises to optimize their communication plans in order to regain, maintain, or strengthen trust in vaccines, vaccination, and immunization programs in general.

This manual serves as a guide to a systematic, standardized global causality assessment process for individual serious adverse events following immunization (AEFI). It is intended to be used by staff at national level (such as members of national AEFI committees) and at subnational level, as well as immunization programme managers and others. It also serves as an educational tool for trainers and researchers and as a ready reference guide on AEFI causality assessment.

Version 1, 18 January 2021 This manual is designed to assist the countries of the Region of the Americas in planning the operational components of the immunization program to ready them for the COVID-19 vaccine.

This course is exclusively available to ARN personnel. Registration is done through the following link:

This course is only available to VigiFlow users. The aim of this course is to enable learners to effectively use VigiFlow through a comprehensive understanding of the system and practical skill development. Duration: 2 - 2,5 hours

Health workers involved in deployment and implementation of COVID-19 vaccination require vaccine-specific knowledge to ensure safe and efficient vaccine delivery. This training provides key information about COVID-19 vaccines through short instructional videos, vaccine explainers, job aids, topic briefings, and downloadable presentations.

Learning objective: To be able to understand the signal assessment process, to apply the steps explained and to perform a simple signal assessment.

The aim of this course is to introduce key concepts and strategies that will support effective collection of high quality ADR reports prior to their subsequent analysis in your pharmacovigilance center.

This video shows how to store and administer the AstraZeneca COVID-19 vaccine.

WHO explainer: COVID-19 Vaccine Janssen(Ad26.COV2-S [recombinant]) manufacturer Janssen‒Cilag International NV

This document aims to address common myths currently circulating about COVID-19 vaccines to help increase demand among the general population.

This document provides guidance regarding the operation of immunization programs in the context of the COVID-19 pandemic. It contains recommendations on vaccination and epidemiological surveillance for vaccine-preventable diseases (VPDs) in the context of the COVID-19 pandemic, in the Region of the Americas.

These preliminary recommendations provide guidance regarding vaccination of newborns with hepatitis B and BCG vaccines in the context of the COVID-19 pandemic, in order to maintain high vaccination coverage.

The vast amount of data generated by clinical studies of potential therapeutic options for COVID-19 presents important challenges. This new information must be interpreted quickly so that prescribers can make optimal treatment decisions with as little harm to patients as possible, and so that medicines manufacturers can scale-up production rapidly and bolster their supply chains. Interpreting new data quickly will save lives by ensuring that reportedly successful drugs can be administered to as many patients as possible as quickly as possible.

The COVID-19 candidate vaccine landscape and tracker database compiles detailed information on COVID-19 vaccine candidates in development. The landscape is updated regularly - twice a week.

This document provides interim recommendations from the WHO Strategic Advisory Group of Experts (SAGE) on Immunization for influenza vaccination during the COVID-19 pandemic. It also provides programmatic considerations for national authorities planning and conducting their influenza vaccination programmes, as well as research considerations to address current knowledge gaps.